3 results
To characterize the clearance pathways, the routes of excretion, total recovery of radioactivity, pacritinib and its major metabolites in healthy subjects following administration of a single oral dose of 400 mg [14C]pacritinibTo characterize the…
The purpose of this long-term follow-up (LTFU) study (ZOSTER-024) is to evaluate the cell-mediated and humoral immune responses of subjects who previously participated in study ZOSTER-003 and who were in the group receiving 2 doses of 50µg gE/AS01B…
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in…